\-\ Texto\\:\\ \ \(0\)\
\-\ 48\\ year\\ old\\ male\\ diagnosed\\ with\\ multiple\\ sclerosis\\ in\\ 1996\\.\\ at\\ that\\ time\\,\\ patient\\ presented\\ with\\ \\ right\\ lower\\ extremity\\ weakness\\,\\ ataxia\\,\\ spastic\\ gait\\,\\ and\\ decreased\\ visual\\ acuity\\ in\\ right\\ eye\\.\\ \\ lumbar\\ puncture\\ showed\\ 3\\ oligoclonal\\ bands\\,\\ 4\\ white\\ blood\\ cells\\,\\ 3\\ red\\ blood\\ cells\\ and\\ normal\\ glucose\\ and\\ protein\\.\\ mri\\ showed\\ t2\\ hyperintensities\\ and\\ scattered\\ enhancement\\.\ \(0\)\
\-\ \\ \\ \\ \\ \\ patient\\ now\\ presents\\ \\(2010\\)\\ with\\ progressively\\ worsening\\ symptoms\\ over\\ the\\ past\\ 4\\ months\\.\\ mri\\ was\\ ordered\\ to\\ evaluate\\ for\\ enhancing\\ plaques\\.\ \(0\)\
\-\ interferon\\ beta\\ 1\\-a\ \(0\)\
\-\ sagittal\\ and\\ axial\\ t1\\,\\ axial\\ t2\\,\\ coronal\\ and\\ sagittal\\ t2\\ fair\\ and\\ post\\ gadolinium\\ axial\\ images\\ through\\ the\\ brain\\ were\\ performed\\.\\ numerous\\ foci\\ of\\ periventricular\\,\\ periatrial\\ and\\ deep\\ white\\ matter\\ signal\\ abnormalities\\.\\ there\\ is\\ diffuse\\ foci\\ of\\ parenchymal\\ trophy\\.\\ there\\ are\\ additional\\ foci\\ of\\ signal\\ changes\\ within\\ the\\ subcortical\\ white\\ matter\\ of\\ the\\ bilaeral\\ hemispheres\\.\\ also\\ with\\ interval\\ development\\ of\\ several\\ new\\ lesions\\.\\ \\ following\\ contrast\\ administration\\,\\ multiple\\ enhancing\\ lesions\\ are\\ noted\\ in\\ the\\ right\\ frontal\\ and\\ parietal\\ lobes\\.\ \(0\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ 48\\ year\\ old\\ male\\ diagnosed\\ with\\ multiple\\ sclerosis\\ in\\ 1996\\.\\ at\\ that\\ time\\,\\ patient\\ presented\\ with\\ \\ right\\ lower\\ extremity\\ weakness\\,\\ ataxia\\,\\ spastic\\ gait\\,\\ and\\ decreased\\ visual\\ acuity\\ in\\ right\\ eye\\.\\ \\ lumbar\\ puncture\\ showed\\ 3\\ oligoclonal\\ bands\\,\\ 4\\ white\\ blood\\ cells\\,\\ 3\\ red\\ blood\\ cells\\ and\\ normal\\ glucose\\ and\\ protein\\.\\ mri\\ showed\\ t2\\ hyperintensities\\ and\\ scattered\\ enhancement\\.\ \(0\)\
\-\ \\ \\ \\ \\ \\ patient\\ now\\ presents\\ \\(2010\\)\\ with\\ progressively\\ worsening\\ symptoms\\ over\\ the\\ past\\ 4\\ months\\.\\ mri\\ was\\ ordered\\ to\\ evaluate\\ for\\ enhancing\\ plaques\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ 1996\\.\\:\\ 0\\.05653411088130687\ \(0\)\
\-\ cells\\:\\ 0\\.050204347167032926\ \(0\)\
\-\ spastic\\:\\ 0\\.04934854858818068\ \(0\)\
\-\ oligoclonal\\:\\ 0\\.047713797296501485\ \(0\)\
\-\ hyperintensities\\:\\ 0\\.04427054726539719\ \(0\)\
\-\ white\\:\\ 0\\.041525336449992935\ \(0\)\
\-\ showed\\:\\ 0\\.04105206253368054\ \(0\)\
\-\ foci\\:\\ 0\\.04030795546322028\ \(0\)\
\-\ acuity\\:\\ 0\\.03942513713905752\ \(0\)\
\-\ 2010\\:\\ 0\\.038748409519050085\ \(0\)\
\-\ puncture\\:\\ 0\\.03853604661155373\ \(0\)\
\-\ bands\\:\\ 0\\.0373768963901992\ \(0\)\
\-\ t2\\:\\ 0\\.03543719807692824\ \(0\)\
\-\ plaques\\:\\ 0\\.034963129348952\ \(0\)\
\-\ 4\\:\\ 0\\.034886035240718614\ \(0\)\
\-\ blood\\:\\ 0\\.034174521208927465\ \(0\)\
\-\ sclerosis\\:\\ 0\\.03372873882886094\ \(0\)\
\-\ progressively\\:\\ 0\\.033670408196266606\ \(0\)\
\-\ ataxia\\:\\ 0\\.03345804528877025\ \(0\)\
\-\ glucose\\:\\ 0\\.03345804528877025\ \(0\)\
\-\ red\\:\\ 0\\.03266527177492239\ \(0\)\
\-\ 1\\-a\\:\\ 0\\.032291276278265564\ \(0\)\
\-\ trophy\\:\\ 0\\.032291276278265564\ \(0\)\
\-\ bilaeral\\:\\ 0\\.032291276278265564\ \(0\)\
\-\ protein\\:\\ 0\\.03212235622800867\ \(0\)\
\-\ 48\\:\\ 0\\.03062849403470229\ \(0\)\
\-\ periatrial\\:\\ 0\\.02975227561687382\ \(0\)\
\-\ enhancing\\:\\ 0\\.029450038822909443\ \(0\)\
\-\ ordered\\:\\ 0\\.029448555885492726\ \(0\)\
\-\ 3\\:\\ 0\\.029318322735626956\ \(0\)\
\-\ gait\\:\\ 0\\.029151915875567914\ \(0\)\
\-\ scattered\\:\\ 0\\.029151915875567914\ \(0\)\
\-\ mri\\:\\ 0\\.028765946592155603\ \(0\)\
\-\ visual\\:\\ 0\\.02838004396598677\ \(0\)\
\-\ fair\\:\\ 0\\.028267055440653437\ \(0\)\
\-\ axial\\:\\ 0\\.026799906330416172\ \(0\)\
\-\ lumbar\\:\\ 0\\.026620768305307057\ \(0\)\
\-\ multiple\\:\\ 0\\.02637078393376218\ \(0\)\
\-\ eye\\:\\ 0\\.026259412506314368\ \(0\)\
\-\ interferon\\:\\ 0\\.025728054779261697\ \(0\)\
\-\ evaluate\\:\\ 0\\.02530568687367819\ \(0\)\
\-\ sagittal\\:\\ 0\\.024969572545834283\ \(0\)\
\-\ worsening\\:\\ 0\\.024648204911361157\ \(0\)\
\-\ matter\\:\\ 0\\.024648204911361157\ \(0\)\
\-\ weakness\\:\\ 0\\.023249900022185965\ \(0\)\
\-\ diagnosed\\:\\ 0\\.023019744738424948\ \(0\)\
\-\ extremity\\:\\ 0\\.022894937506538007\ \(0\)\
\-\ beta\\:\\ 0\\.021703833941649573\ \(0\)\
\-\ now\\:\\ 0\\.021400114210268478\ \(0\)\
\-\ past\\:\\ 0\\.0198915712230508\ \(0\)\
\-\ subcortical\\:\\ 0\\.019064470737444224\ \(0\)\
\-\ decreased\\:\\ 0\\.018613600019960142\ \(0\)\
\-\ periventricular\\:\\ 0\\.01803552427053433\ \(0\)\
\-\ time\\:\\ 0\\.017682060272815478\ \(0\)\
\-\ months\\:\\ 0\\.017098471023370455\ \(0\)\
\-\ presented\\:\\ 0\\.01706489109906527\ \(0\)\
\-\ enhancement\\:\\ 0\\.016780137480754843\ \(0\)\
\-\ lesions\\:\\ 0\\.01675868502816079\ \(0\)\
\-\ hemispheres\\:\\ 0\\.01667706427445122\ \(0\)\
\-\ right\\:\\ 0\\.016513401265758548\ \(0\)\
\-\ signal\\:\\ 0\\.016506039049617425\ \(0\)\
\-\ over\\:\\ 0\\.01593877355413892\ \(0\)\
\-\ \\,\\:\\ 0\\.015865791385628564\ \(0\)\
\-\ symptoms\\:\\ 0\\.015601886277642045\ \(0\)\
\-\ parenchymal\\:\\ 0\\.015386072919872668\ \(0\)\
\-\ interval\\:\\ 0\\.015349983921912919\ \(0\)\
\-\ gadolinium\\:\\ 0\\.014847415711240814\ \(0\)\
\-\ lower\\:\\ 0\\.014079575599735257\ \(0\)\
\-\ numerous\\:\\ 0\\.014036306967978616\ \(0\)\
\-\ lobes\\:\\ 0\\.013793635226069455\ \(0\)\
\-\ development\\:\\ 0\\.013632850634284746\ \(0\)\
\-\ parietal\\:\\ 0\\.01337264633715379\ \(0\)\
\-\ coronal\\:\\ 0\\.013033051472302992\ \(0\)\
\-\ administration\\:\\ 0\\.012995092545432858\ \(0\)\
\-\ presents\\:\\ 0\\.012788602897493962\ \(0\)\
\-\ deep\\:\\ 0\\.012670081132946834\ \(0\)\
\-\ additional\\:\\ 0\\.012551086791758231\ \(0\)\
\-\ patient\\:\\ 0\\.012550797522584438\ \(0\)\
\-\ abnormalities\\:\\ 0\\.011497306306586874\ \(0\)\
\-\ male\\:\\ 0\\.011320187090750718\ \(0\)\
\-\ new\\:\\ 0\\.010907648266668712\ \(0\)\
\-\ that\\:\\ 0\\.01081304563046757\ \(0\)\
\-\ several\\:\\ 0\\.010062611119862225\ \(0\)\
\-\ t1\\:\\ 0\\.009921229070418475\ \(0\)\
\-\ post\\:\\ 0\\.009856538582682395\ \(0\)\
\-\ frontal\\:\\ 0\\.009832571188583727\ \(0\)\
\-\ normal\\:\\ 0\\.00981401065640367\ \(0\)\
\-\ diffuse\\:\\ 0\\.009476217657052435\ \(0\)\
\-\ brain\\:\\ 0\\.009418870048728066\ \(0\)\
\-\ there\\:\\ 0\\.00931659748325999\ \(0\)\
\-\ changes\\:\\ 0\\.008970871707820734\ \(0\)\
\-\ through\\:\\ 0\\.008889952448428091\ \(0\)\
\-\ following\\:\\ 0\\.008883801307330214\ \(0\)\
\-\ performed\\:\\ 0\\.008727393154678824\ \(0\)\
\-\ and\\:\\ 0\\.008571857415819926\ \(0\)\
\-\ are\\:\\ 0\\.008533874524026387\ \(0\)\
\-\ at\\:\\ 0\\.008481781339425882\ \(0\)\
\-\ in\\:\\ 0\\.0077178979879167576\ \(0\)\
\-\ noted\\:\\ 0\\.007419125232427083\ \(0\)\
\-\ was\\:\\ 0\\.007240128367865838\ \(0\)\
\-\ were\\:\\ 0\\.00710727595857114\ \(0\)\
\-\ contrast\\:\\ 0\\.0070065043472817045\ \(0\)\
\-\ year\\:\\ 0\\.00700443420712758\ \(0\)\
\-\ old\\:\\ 0\\.006409777266390144\ \(0\)\
\-\ also\\:\\ 0\\.006170767742381507\ \(0\)\
\-\ images\\:\\ 0\\.006004629640840125\ \(0\)\
\-\ within\\:\\ 0\\.005971177320095537\ \(0\)\
\-\ for\\:\\ 0\\.00534145163840817\ \(0\)\
\-\ \\(\\:\\ 0\\.005292027298489821\ \(0\)\
\-\ \\)\\:\\ 0\\.005227382359804433\ \(0\)\
\-\ to\\:\\ 0\\.0031287040911574084\ \(0\)\
\-\ the\\:\\ 0\\.003038445817662106\ \(0\)\
\-\ with\\:\\ 0\\.003000107079227942\ \(0\)\
\-\ of\\:\\ 0\\.0021337692453844035\ \(0\)\
\-\ \\.\\:\\ 0\\.0020805588921521626\ \(0\)\
\-\ is\\:\\ 0\\.002059673180896431\ \(0\)\
